9-Cyano-1-azapaullone (Cazpaullone), a Glycogen Synthase Kinase-3 (GSK-3) inhibitor activating pancreatic β cell protection and replication

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2196-2207

  Stukenbrock, Hendrik ^a   Mussmann, Rainer ^b   Geese, Marcus ^b   Ferandin, Yoan ^c   Lozach, Olivier ^c   Lemcke, Thomas ^d   Kegel, Simone ^b   Lomow, Alexander ^b   Burk, Ulrike ^b   Dohrmann, Cord ^b   Meijer, Laurent ^c   Austen, Matthias ^b   Kunick, Conrad ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b DeveloGen AG   (Germany)

^c STATION BIOLOGIQUE   (France)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZAKENPAULLONE; 6 OXO 5,6,7,12 TETRAHYDROPYRIDO[3',2':2,3]AZEPINO[4,5 B]INDOLE 9 CARBONITRILE; 9 BROMO 5,7 DIHYDRO 6H [1]BENZOFURO[3,2 D][1]BENZAZEPIN 6 ONE; 9 BROMO 7,12 DIHYDROPYRIDO[4',3':2,3]AZEPINO[4,5 B]INDOL 6(5H) ONE; 9 CYANO 1 AZAPAULLONE; ALSTERPAULLONE; BENZAZEPINE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDOLE DERIVATIVE; KENPAULLONE; MESSENGER RNA; PAULLONE DERIVATIVE; TRANSCRIPTION FACTOR PAX4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL DIVISION; CELL GROWTH; CELL MATURATION; CELL PROTECTION; CELL REGENERATION; DIABETES MELLITUS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PROTEIN EXPRESSION; RAT; STIMULATION; SYNTHESIS;

ANIMALS; AZEPINES; BINDING SITES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; INSULIN-SECRETING CELLS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41849116324     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701582f     Document Type: Article

References (62)

1. Zimmet, P.; Alberti, K. G. M. M.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787.
2. King, H.; Aubert, R. E.; Herman, W. H. Global burden of diabetes, 1995-2025 prevalence, numerical estimates, and projections. Diabetes Care 1998, 21, 1414-1431.
3. Nathan, D. Finding new treatments for diabetes - how many, how fast. .how good. N. Engl. J. Med. 2007, 356, 437-440.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329, 977-986.
5. U.K. Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998, 317, 703-713.
6. Meier, J.; Bhushan, A.; Butler, A.; Rizza, R.; Butler, P. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration. Diabetologia 2005, 48, 2221-2228.
7. Sherry, N.; Tsai, E.; Herold, K. Natural history of beta-cell function in type 1 diabetes. Diabetes 2005, 54 (Suppl. 2), 32-39.
8. Butler, A.; Janson, J.; Bonner-Weir, S.; Ritzel, R.; Rizza, R.; Butler, P. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52, 102-110.
9. Yoon, K.; Ko, S.; Cho, J.; Lee, J.; Ahn, Y.; Song, K.; Yoo, S.; Kang, M.; Cha, B.; Lee, K.; Son, H.; Kang, S.; Kim, H.; Lee, I.; Bonner-Weir, S. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J. Clin. Endocrinol. Metab. 2003, 88, 2300-2308.
10. Wang, T.; Bonner-Weir, S.; Oates, P.; Chulak, M.; Simon, B.; Merlino, G.; Schmidt, E.; Brand, S. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J. Clin. Invest. 1993, 92, 1349-1356.
11. Rooman, I.; Bouwens, L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57B16/J mice treated with alloxan. Diabetologia 2004, 47, 259-265.
12. Suarez-Pinzon, W.; Yan, Y.; Power, R.; Brand, S.; Rabinovitch, A. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 2005, 54, 2596-2601.
13. A Study in Type 2 Diabetic Patients with Repeated Doses of E1 in Combination with G1; Identifier NCT00239187; U.S. National Institute of Health, 2007; www.clinicaltrials.gov.
14. Larsen, C.; Faulenbach, M.; Vaag, A.; Vølund, A.; Ehses, J.; Seifert, B.; Mandrup-Poulsen, T.; Donath, M. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356, 1517-1526.
15. Boucher, M.; Selander, L.; Carlsson, L.; Edlund, H. Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. J. Biol. Chem. 2006, 281, 6395-6403.
16. Mussmann, R.; Geese, M.; Harder, F.; Kegel, S.; Andag, U.; Lomow, A.; Burk, U.; Onichtchouk, D.; Dohrmann, C.; Austen, M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J. Biol. Chem. 2007, 282, 12030-12037.
17. Srinivasan, S.; Ohsugi, M.; Liu, Z.; Fatrai, S.; Bernal-Mizrachi, E.; Permutt, M. A. Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes 2005, 54, 968-975.
18. Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase 3/factor A. EMBO J. 1990, 9, 2431-2438.
19. Elghazi, L.; Rachdi, L.; Weiss, A.; Cras-Méneur, C.; Bernal-Mizrachi, E. Regulation of beta-cell mass and function by the Akt/protein kinase B signalling pathway. Diabetes Obes. Metab. 2007, 9 (Suppl. 2), 147-57.
20. Rulifson, I.; Karnik, S.; Heiser, P.; ten Berge, D.; Chen, H.; Gu, X.; Taketo, M.; Nusse, R.; Hebrok, M.; Kim, S. Wnt signaling regulates pancreatic beta cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 6247-6252.
21. Benbow, J.; Helal, C.; Kung, D.; Wager, T. Glycogen synthase kinase-3 (GSK-3): a kinase with exeptional therapeutic potential. Annu. Rep. Med. Chem. 2005, 40, 135-147.
22. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discovery 2004, 3, 479-487.
23. Frame, S.; Zheleva, D. Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin. Ther. Targets 2006, 10, 429-444.
24. Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase kinase-3. Trends Pharmacol. Sci. 2004, 25, 471-480.
25. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jorgensen, F. S.; Lemcke, T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. J. Med. Chem. 2004, 47, 22-36.
26. Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.
27. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y.-Z.; Mandelkow, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J. Biol. Chem. 2001, 276, 251-260.
28. Meijer, L.; Skaltsounis, A.-L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem. Biol. 2003, 10, 1255-1266.
29. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935-946.
30. Coghlan, M. P.; Culbert, A. A.; Cross, D. A. E.; Corcoran, S. L.; Yates, J. D.; Pearce, N. J.; Rausch, O. L.; Murphy, G. J.; Carter, P. S.; Cox, L. R.; Mills, D.; Brown, M. J.; Haigh, D.; Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A. D.; Holder, J. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7, 793-803.
31. Kozikowski, A. P.; Gaisina, I. N.; Yuan, H.; Petukhov, P. A.; Bond, S. Y.; Fedolak, A.; Caldarone, B.; McGonigle, P. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3β therapies for bipolar disorders. J. Am. Chem. Soc. 2007, 129, 8328-8332.
32. Zhang, H.-C.; Boñaga, L. V. R.; Ye, H.; Derian, C. K.; Damiano, B. P.; Maryanoff, B. E. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2007, 17, 2863-2868.
33. Kunick, C.; Lauenroth, K.; Leost, M.; Meijer, L.; Lemcke, T. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2004, 14, 413-416.
34. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 2003, 333, 393-407.
35. Kunick, C. Synthese[b]-kondensierter Azepindione durch Dealkoxycarbonylierung. Arch. Pharm. (Weinheim, Ger.) 1991, 324, 579-581.
36. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 1999, 42, 2909-2919.
37. Taylor, E. C.; Knopf, R. J.; Cogliano, J. A.; Barton, J. W.; Pfleiderer, W. Pteridines. XXIII. A facile pyrimidine ring cleavage. J. Am. Chem. Soc. 1960, 82, 6058-6064.
38. Cragoe, E. J. Diuretic (Aminopyridylcarbonyl)guanidines. Ger. Offen. DE 1963317, 1970.
39. Strauss, C. R. A combinatorial approach to the development of environmentally benign organic chemical preparations. Aust. J. Chem. 1999, 53, 83-96.
40. Strauss, C. R.; Trainor, R. W. Development in microwave-assisted organic chemistry. Aust. J. Chem. 1995, 48, 1665-1692.
41. McOmie, J. F. W.; Watts, M. L.; West, D. E. Demethylation of aryl methyl ethers by boron tribromide. Tetrahedron 1968, 24, 2289-2292.
42. Petrassi, H. M.; Sharpless, K. B.; Kelly, J. W. The copper-mediated cross-coupling of phenylboronic acids and N-hydroxyphthalimide at room temperature: synthesis of aryloxyamines. Org. Lett. 2001, 3, 139-142.
43. Liao, Y.; Kozikowski, A. P.; Guidotti, A.; Costa, E. Synthesis and pharmacological evaluation of benzofuranacetamides as "antineophobic" mitochondrial DBI receptor complex ligands. Bioorg. Med. Chem. Lett. 1998, 8, 2099-2102.
44. Castro, J. L.; Baker, R.; Guiblin, A. R.; Hobbs, S. C.; Jenkins, M. R.; Russel, M. G. N.; Beer, M. S.; Stanton, J. A.; Scholey, K.; Hargreaves, R. J.; Graham, M. I.; Matassa, V. G. Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin-2-yl) methyl]-1-indole and analogues: agonists for the 5-HT1D receptor. J. Med. Chem. 1994, 37, 2023-3032.
45. Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Leost, M.; Meijer, L. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorg. Med. Chem. Lett. 2000, 10, 567-569.
46. Maligres, P. E.; Waters, M. S.; Fleitz, F.; Askin, D. A highly catalytic robust palladium catalyzed cyanation of aryl bromides. Tetrahedron Lett. 1999, 40, 8193-8195.
47. Price, M. CKI, there's more than one: casein kinase I family members in Wnt and hedgehog signaling. Genes Dev. 2006, 20, 399-410.
48. Kitani, K.; Oguma, S.; Nishiki, T.; Ohmori, I.; Galons, H.; Matsui, H.; Meijer, L.; Tomizawa, K. A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo. J. Physiol. Sci. 2007, 57, 235-239.
49. Wei, F.; Nagashima, K.; Ohshima, T.; Saheki, Y.; Lu, Y.; Matsushita, M.; Yamada, Y.; Mikoshiba, K.; Seino, Y.; Matsui, H.; Tomizawa, K. Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat. Med. 2005, 11, 1104-1108.
50. Zaharevitz, D. W.; Gussio, R.; Leost, M.; Senderowicz, A.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999, 59, 2566-2569.
51. Merglen, A.; Theander, S.; Rubi, B.; Chaffard, G.; Wollheim, C.; Maechler, P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 2004, 145, 667-678.
52. Trowbridge, J.; Xenocostas, A.; Moon, R.; Bhatia, M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med. 2006, 12, 89-98.
53. Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105-1137.
54. Brun, T.; Franklin, I.; St-Onge, L.; Biason-Lauber, A.; Schoenle, E.; Wollheim, C.; Gauthier, B. The diabetes-linked transcription factor PAX4 promotes beta-cell proliferation and survival in rat and human islets. J. Cell Biol. 2004, 167, 1123-1135.
55. Brun, T.; Duhamel, D.; Hu He, K.; Wollheim, C.; Gauthier, B. The transcription factor PAX4 acts as a survival gene in INS-1E insulinoma cells. Oncogene 2007, 26, 4261-4271.
56. Brun, T.; Hu He, K.; Lupi, R.; Boehm, B.; Wojtusciszyn, A.; Sauter, N.; Donath, M.; Marchetti, P.; Maedler, K.; Gauthier, B. The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1. Hum. Mol. Genet. 2007 [Epub ahead of print].
57. Parnaud, G.; Bosco, D.; Berney, T.; Pattou, F.; Kerr-Conte, J.; Donath, M.; Bruun, C.; Mandrup-Poulsen, T.; Billestrup, N.; Halban, P. Proliferation of sorted human and rat beta cells. Diabetologia 2008, 51, 91-100.
58. Echalier, A.; Bettayeb, K.; Ferandin, Y.; Lozach, O.; Clement, M.; Valette, A.; Liger, F.; Marquet, B.; Morris, J. C.; Endicott, J. A.; Joseph, B.; Meijer, L. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects and structure of a CDK2/cyclin A/meriolin complex. J. Med. Chem., 2008, 51, 737-751.
59. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
60. Sybyl, version 7.0; Tripos Inc. (1669 South Hanley Road, St. Louis, MO 63111).
61. Clark, M.; Cramer, R. D. I.; Van Obdenbosch, N. The Tripos forcefield. J. Comput. Chem. 1989, 10, 982-1012.
62. Stewart, J. J. MOPAC: a semiemperical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.